In non-small cell lung cancer (NSCLC), ALK fusion proteins, exemplified by EML4-ALK, promote tumor cell proliferation, survival, and migration through persistent activation of downstream oncogenic signaling pathways, representing a key molecular subtype and a primary target for precision therapy [34]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.